ES2192494A1 - Derivados de 1,2,4-triazol con propiedades cannabinoides. - Google Patents

Derivados de 1,2,4-triazol con propiedades cannabinoides.

Info

Publication number
ES2192494A1
ES2192494A1 ES200200740A ES200200740A ES2192494A1 ES 2192494 A1 ES2192494 A1 ES 2192494A1 ES 200200740 A ES200200740 A ES 200200740A ES 200200740 A ES200200740 A ES 200200740A ES 2192494 A1 ES2192494 A1 ES 2192494A1
Authority
ES
Spain
Prior art keywords
triazole derivatives
cannabinoid
properties
cannabinoid properties
sufferers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200200740A
Other languages
English (en)
Other versions
ES2192494B1 (es
Inventor
Nadine Jagerovic
Laza Maria Pilar Goya
Folgado Laura Hernandez
Osoro Ivon Jose Alcorta
Fontelles Maria Isabel Martin
Garcia Margarita Lina Suardiaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Rey Juan Carlos
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Rey Juan Carlos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Rey Juan Carlos filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES200200740A priority Critical patent/ES2192494B1/es
Priority to AU2003215687A priority patent/AU2003215687A1/en
Priority to PCT/ES2003/000126 priority patent/WO2003082833A1/es
Publication of ES2192494A1 publication Critical patent/ES2192494A1/es
Application granted granted Critical
Publication of ES2192494B1 publication Critical patent/ES2192494B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados de 1,2,4-triazol con propiedades cannabinoides. La presente invención se refiere a nuevos derivados de triazol con propiedades cannabinoides, en concreto derivados de 1,2,4-triazol con propiedades cannabinoides. Las aplicaciones terapéuticas principales de los compuestos según la invención y debido a su naturaleza antagonista, entre otros, son la supresión del apetito, la reducción de disquinesia provocada por L-dopa en enfermos de Parkinson, el tratamiento de esquizofrenia aguda y una mejora de las disfunciones cognitivas y de memoria asociadas a la enfermedad de Alzheimer.
ES200200740A 2002-03-27 2002-03-27 Derivados de 1,2,4-triazol con propiedades cannabinoides. Expired - Fee Related ES2192494B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200200740A ES2192494B1 (es) 2002-03-27 2002-03-27 Derivados de 1,2,4-triazol con propiedades cannabinoides.
AU2003215687A AU2003215687A1 (en) 2002-03-27 2003-03-18 1,2,4-triazole derivatives with cannabinoid properties
PCT/ES2003/000126 WO2003082833A1 (es) 2002-03-27 2003-03-18 Derivados de 1,2,4-triazol con propiedades cannabinoides.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200740A ES2192494B1 (es) 2002-03-27 2002-03-27 Derivados de 1,2,4-triazol con propiedades cannabinoides.

Publications (2)

Publication Number Publication Date
ES2192494A1 true ES2192494A1 (es) 2003-10-01
ES2192494B1 ES2192494B1 (es) 2005-02-16

Family

ID=28459667

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200740A Expired - Fee Related ES2192494B1 (es) 2002-03-27 2002-03-27 Derivados de 1,2,4-triazol con propiedades cannabinoides.

Country Status (3)

Country Link
AU (1) AU2003215687A1 (es)
ES (1) ES2192494B1 (es)
WO (1) WO2003082833A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP4436369B2 (ja) 2004-01-28 2010-03-24 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ベンゾジオキソール類およびそれらのｃｂ１アンタゴニストとしての使用
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
WO2008081204A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
TW201021797A (en) 2008-12-04 2010-06-16 Nat Univ Tsing Hua 1,2,3-triazole derivatives as new cannabinoid-1 receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators
JPH08245315A (ja) * 1995-03-16 1996-09-24 Nippon Soda Co Ltd トリアゾール誘導体および有害生物防除剤
WO1997049395A1 (en) * 1996-06-25 1997-12-31 Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators
JPH08245315A (ja) * 1995-03-16 1996-09-24 Nippon Soda Co Ltd トリアゾール誘導体および有害生物防除剤
WO1997049395A1 (en) * 1996-06-25 1997-12-31 Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CZOLLNER, L. et al.: Synthesis of new 1,5-diphenyl-3-1-H-1,2,4 triazoles substituted with H-alkyl, or carboxyl groups at C-3. Arch. Pharm., 1990, Vol. 323, pßginas 225-227. Pßgina 225, compuesto VII. *
HOQUE, A.K.M. et al.: 1,3 dipolar cyclo additions induced by cation radicals. Formation of 1,2,4 triazoles from oxidative addition of 1,4 diphenylazomethane and aryl aldehyde phenylhydrazones to nitriles. Tetrahedron Letters, 1985, Vol. 26, nö 46, páginas 5655-5658. Compuesto 3, páginas 5655 y compuestos 1,2, página 5656. *
Patent Abstracts of Japan [CD-ROM] & JP 08245315 A (NIPPON SODA CO LTD) 24.09.1996, resumen *

Also Published As

Publication number Publication date
AU2003215687A1 (en) 2003-10-13
ES2192494B1 (es) 2005-02-16
WO2003082833A1 (es) 2003-10-09

Similar Documents

Publication Publication Date Title
ES2192494A1 (es) Derivados de 1,2,4-triazol con propiedades cannabinoides.
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
IL169897A0 (en) Sustituted heterocycles
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CA2515596A1 (en) Cannabinoid receptor ligands and uses thereof
MXPA05013294A (es) Ligandos del receptor de cannabinoides y usos de los mismos.
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
MXPA05010164A (es) Ligandos de receptores de canabinoides y sus usos.
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
SG157231A1 (en) Substituted p-diaminobenzene derivatives
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
WO2007017511A3 (de) Verbindungen zur behandlung der alzheimer erkrankung
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL190508A (en) History 2-Amino-3-Methoxy-n- Methylpropenamide preserved in halogen, Pharmaceuticals containing @ them @ and use @ them
BRPI0415355A (pt) triarilimidazóis
TW200504051A (en) Novel acridine derivatives and their use as medicaments
PL1824338T3 (pl) 3-Cyklopropylo-4-(3-amino-2-metylobenzoilo)pirazole i ich zastosowanie jako herbicydów

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031001

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192494B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180808